Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 13, 2024
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.
Read more at globenewswire.com
